Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins European approval for Lantus follow-up Toujeo

Long-acting insulin is a key part of the company's growth plans

Sanofi Toujeo insulin glargine penSanofi has won European approval for its new long-acting insulin Toujeo as a treatment for adults with type 1 and 2 diabetes.

Toujeo (insulin glargine [rDNA origin[injection, 300 U/mL) is the company's follow-up product to its €6.3bn a year blockbuster Lantus (insulin glargine) and a key part of the company's growth plans.

Pierre Chancel, senior vice-president of global diabetes at Sanofi, said: "The EU marketing authorisation for Toujeo represents a significant milestone for Sanofi, expanding our integrated portfolio of solutions for people with diabetes in Europe.”

Toujeo's marketing authorisation from the European Commission came on the back of the EDITION clinical trial programme. Its package of phase III trials compared Toujeo to Lantus and found Toujeo to have comparable glycaemic control, a lower rate of hypoglycaemia in patients with type 2 diabetes and a similar incidence of hypoglycaemia in type 1 diabetes patients.

The biologic's European approval comes almost exactly two months after US regulator the FDA gave it the green light and less than one month after the French pharma company's new chief executive Olivier Brandicort took the helm.

Given the importance of Lantus to Sanofi - last year it accounted for 18% of the company's entire sales - and the looming threat of biosimilar  competition from Lilly/Boehringer, Toujeo's performance will be one of Brandicort's first major tests.

However, the company will have slightly longer to establish Toujeo than it originally expected after regulatory filings for Lilly's insulin peglispro were delayed recently due to safety concerns.

Article by
Dominic Tyer

29th April 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....